Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atazanavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT1A1 | P22309 | 3/20 | 0.91 |
| ▸ | MLNR | O43193 | 1/20 | 0.91 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.91 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.91 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.91 |
| ▸ | CCKAR | P32238 | 1/20 | 0.91 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.91 |
| ▸ | GHSR | Q92847 | 1/20 | 0.91 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.91 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.91 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.91 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | CTSD | P07339 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | PGC | P20142 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atazanavir SCHEMBL28121836 | 0.96 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL291519 | 0.96 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL341700 | 0.96 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL29362158 | 0.96 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL27785902 | 0.96 | UGT1A1 (0.94) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL21565117 | 0.96 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL22847477 | 0.96 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629941 | 0.96 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL20629937 | 0.96 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 | |
| Atazanavir SCHEMBL1559640 | 0.96 | UGT1A1 (1.00) | UGT1A1MLNRNR1I2SLCO2B1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6877 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387515-A1 | HYPOIMMUNOGENIC BIOMIMETIC NANOVESICLE GENE EDITING SYSTEM FOR HIV INFECTION | MALCOLM THOMAS (US) | 2025-12-25 | — | — | US | claimed |
| US-12459989-B2 | Antibody therapies for human immunodeficiency virus (HIV) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | claimed |
| US-20250319060-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2025-10-16 | — | — | US | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-08-07 | — | — | US | claimed |
| EP-4577225-A2 | CHIMERIC CYTOKINE RECEPTORS AND METHODS OF USE | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-07-02 | — | — | EP | claimed |
| CN-120053378-A | Ginsenoside Rh2 composition and preparation method and application thereof | 澳门大学 | 2025-05-30 | — | — | CN | claimed |
| EP-4547711-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4547335-A2 | ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF | Modex Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| CN-119866222-A | Chimeric cytokine receptors and methods of use thereof | 小利兰·斯坦福大学理事会 | 2025-04-22 | — | — | CN | claimed |
| EP-1585527-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2005-10-19 | — | — | EP | claimed |
| EP-1583542-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2005-10-12 | — | — | EP | claimed |
| WO-2005082385-A1 | STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS | OSTEOLOGIX A/S (DK) | 2005-09-09 | — | — | WO | claimed |
| EP-1542718-A2 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | Xie, Dong (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050089840-A1 | Antifusogenic; antiviral conjugates; point mutations | FRONTIER BIOTECHNOLOGIES CO., LTD. (CN) | 2005-04-28 | — | — | US | claimed |
| US-20040224917-A1 | Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | claimed |
| US-20040224916-A1 | Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine) | GILEAD SCIENCES, INC. | 2004-11-11 | — | — | US | claimed |
| WO-2004064846-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004064845-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004029201-A2 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION | FRONTIER BIOTECHNOLOGIES CO., LTD (CN) | 2004-04-08 | — | — | WO | claimed |